Investigational Drug Information for Dipraglurant
✉ Email this page to a colleague
What is the development status for investigational drug Dipraglurant?
Dipraglurant is an investigational drug.
There have been 5 clinical trials for Dipraglurant.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 6th 2021.
The most common disease conditions in clinical trials are Parkinson Disease, Dyskinesias, and Dyskinesia, Drug-Induced. The leading clinical trial sponsors are Addex Pharma S.A., Johns Hopkins University, and [disabled in preview].
There are fifteen US patents protecting this investigational drug and two hundred and sixty-one international patents.
Summary for Dipraglurant
| US Patents | 15 |
| International Patents | 261 |
| US Patent Applications | 47 |
| WIPO Patent Applications | 32 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 2 (2021-08-06) |
| Vendors | 35 |
Recent Clinical Trials for Dipraglurant
| Title | Sponsor | Phase |
|---|---|---|
| Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy | Addex Pharma S.A. | Phase 2/Phase 3 |
| Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm | Addex Pharma S.A. | Phase 2 |
| Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy | Addex Pharma S.A. | Phase 2/Phase 3 |
Clinical Trial Summary for Dipraglurant
Top disease conditions for Dipraglurant
Top clinical trial sponsors for Dipraglurant
US Patents for Dipraglurant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Dipraglurant | ⤷ Sign Up | Glucocerebrosidase modulators and uses thereof | Alectos Therapeutics Inc. (Burnaby, CA) | ⤷ Sign Up |
| Dipraglurant | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Dipraglurant | ⤷ Sign Up | Pharmaceutical formulations | Auspex Pharmaceuticals, Inc. (La Jolla, CA) | ⤷ Sign Up |
| Dipraglurant | ⤷ Sign Up | Composition and method for treating neurological disease | Osmotica Kereskedelmi es Szolgaltato Korlatolt Feleossegu Tarsasag (Budapest, HU) | ⤷ Sign Up |
| Dipraglurant | ⤷ Sign Up | Composition and method for treating neurological disease | Osmotica Kereskedelmi es Szolgaltato Korlatolt Felelossegu Tarsasag (Budapest, HU) | ⤷ Sign Up |
| Dipraglurant | ⤷ Sign Up | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | Heptares Therapeutics Limited (Welwyn Garden, GB) | ⤷ Sign Up |
| Dipraglurant | ⤷ Sign Up | Organic compounds | Novartis AG (Basel, CH) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Dipraglurant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Dipraglurant | European Patent Office | EP3087056 | 2033-12-23 | ⤷ Sign Up |
| Dipraglurant | Japan | JP2017502961 | 2033-12-23 | ⤷ Sign Up |
| Dipraglurant | World Intellectual Property Organization (WIPO) | WO2015095963 | 2033-12-23 | ⤷ Sign Up |
| Dipraglurant | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| Dipraglurant | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| Dipraglurant | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| Dipraglurant | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
